FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 COVID-19: “It could take months to build research up again” July 1, 2020 EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Load more HOT NEWS 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ Cancer in My Community: Working to Eliminate the Stigma of Cancer... MAP Congress 2020: Molecular Analysis for Precision Oncology
